https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.107

Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study / Lee-Ying, R.M., Saieva, C., Nuzzo, P.V., Malgeri, A., Fotia, G., Zanardi, E., Rossetti, S., Valenca, L.B., Patrikidou, A., Modesti, M., Martins Oliveira, T., Pignata, S., Fornarini, G., Procopio, G., Santini, D., Sweeney, C., Heng, D.Y.C., De Giorgi, U., Russo, A., Francini, E.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 41:(2023), pp. 107-107. [10.1200/JCO.2023.41.6_suppl.107]

Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study

Modesti, Mikol;Francini, Edoardo
Conceptualization
2023

Abstract

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.107
2023
Lee-Ying, Richard M.; Saieva, Calogero; Nuzzo, Pier Vitale; Malgeri, Andrea; Fotia, Giuseppe; Zanardi, Elisa; Rossetti, Sabrina; Valenca, Loana Bueno;...espandi
1c - Abstract su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1342058
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact